Filing Details
- Accession Number:
- 0001209191-20-022241
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-04-01 18:19:42
- Reporting Period:
- 2020-03-30
- Accepted Time:
- 2020-04-01 18:19:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1714899 | Denali Therapeutics Inc. | DNLI | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1666236 | E. Steve Krognes | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | Cfo And Treasurer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-03-30 | 1,428 | $19.48 | 1,006,488 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.46 to $19.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.